These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 18926156)

  • 1. Systemic exposure of everolimus after stent implantation: a pharmacokinetic study.
    Wiemer M; Seth A; Chandra P; Neuzner J; Richardt G; Piek JJ; Desaga M; Macaya C; Bol CJ; Miquel-Hebert K; De Roeck K; Serruys PW
    Am Heart J; 2008 Oct; 156(4):751.e1-7. PubMed ID: 18926156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).
    Kereiakes DJ; Cutlip DE; Applegate RJ; Wang J; Yaqub M; Sood P; Su X; Su G; Farhat N; Rizvi A; Simonton CA; Sudhir K; Stone GW
    J Am Coll Cardiol; 2010 Dec; 56(25):2084-9. PubMed ID: 21144968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus PK trial: a pharmacokinetic study of the sirolimus-eluting Bx velocity stent in patients with de novo coronary lesions.
    Vetrovec GW; Rizik D; Williard C; Snead D; Piotrovski V; Kopia G
    Catheter Cardiovasc Interv; 2006 Jan; 67(1):32-7. PubMed ID: 16342216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic sub-study in the SPIRIT III Randomized and Controlled Trial of XIENCE V everolimus eluting coronary stent system.
    Wang Q; Pierson W; Sood P; Bol C; Cannon L; Gordon P; Saucedo J; Sudhir K
    J Interv Cardiol; 2010 Feb; 23(1):26-32. PubMed ID: 20040005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature.
    Lammer J; Scheinert D; Vermassen F; Koppensteiner R; Hausegger KA; Schroë H; Menon RM; Schwartz LB
    J Vasc Surg; 2012 Feb; 55(2):400-5. PubMed ID: 22051872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Xience V everolimus-eluting coronary stent.
    Kukreja N; Onuma Y; Serruys PW
    Expert Rev Med Devices; 2009 May; 6(3):219-29. PubMed ID: 19419279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood concentrations of everolimus are markedly increased by ketoconazole.
    Kovarik JM; Beyer D; Bizot MN; Jiang Q; Shenouda M; Schmouder RL
    J Clin Pharmacol; 2005 May; 45(5):514-8. PubMed ID: 15831774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of rapamycin-eluting stents in miniswine coronary model.
    Yu MY; Gao RL; Jiang J; Cheng SJ; Yuan JQ; Wang CN; Zheng JG; Meng L; Zi ZJ
    Chin Med J (Engl); 2004 Oct; 117(10):1459-63. PubMed ID: 15498365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid chromatography-tandem mass spectrometry outperforms fluorescence polarization immunoassay in monitoring everolimus therapy in renal transplantation.
    Moes DJ; Press RR; de Fijter JW; Guchelaar HJ; den Hartigh J
    Ther Drug Monit; 2010 Aug; 32(4):413-9. PubMed ID: 20535052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry.
    Onuma Y; Kukreja N; Piazza N; Eindhoven J; Girasis C; Schenkeveld L; van Domburg R; Serruys PW;
    J Am Coll Cardiol; 2009 Jul; 54(3):269-76. PubMed ID: 19589442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Robust, high-throughput LC-MS/MS method for therapeutic drug monitoring of cyclosporine, tacrolimus, everolimus, and sirolimus in whole blood.
    Koster RA; Dijkers EC; Uges DR
    Ther Drug Monit; 2009 Feb; 31(1):116-25. PubMed ID: 19065123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry).
    Kaltoft A; Jensen LO; Maeng M; Tilsted HH; Thayssen P; Bøttcher M; Lassen JF; Krusell LR; Rasmussen K; Hansen KN; Pedersen L; Johnsen SP; Sørensen HT; Thuesen L
    J Am Coll Cardiol; 2009 Feb; 53(8):658-64. PubMed ID: 19232897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment.
    Kovarik JM; Sabia HD; Figueiredo J; Zimmermann H; Reynolds C; Dilzer SC; Lasseter K; Rordorf C
    Clin Pharmacol Ther; 2001 Nov; 70(5):425-30. PubMed ID: 11719728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal dosing and duration of oral everolimus to inhibit in-stent neointimal growth in rabbit iliac arteries.
    Waksman R; Pakala R; Baffour R; Hellinga D; Seabron R; Kolodgie F; Virmani R
    Cardiovasc Revasc Med; 2006; 7(3):179-84. PubMed ID: 16945826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of diabetes mellitus on early and long-term results of percutaneous drug-eluting stent implantation for unprotected left main coronary disease.
    Sheiban I; Garrone P; Sillano D; Biondi-Zoccai G; Sciuto F; Omedè P; Lombardi P; Meliga E; Anselmino M; Trevi GP; Moretti C
    J Cardiovasc Med (Hagerstown); 2008 Dec; 9(12):1246-53. PubMed ID: 19001932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic exposure of sirolimus after coronary stent implantation in patients with de novo coronary lesions: Supralimus-Core® pharmacokinetic study.
    Thakkar AS; Abhyankar AD; Dani SI; Banker DN; Singh PI; Parmar SA; Mehta AA
    Indian Heart J; 2012; 64(3):273-9. PubMed ID: 22664810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I multiple-dose escalation study characterizing pharmacokinetics and safety of ABT-578 in healthy subjects.
    Karyekar CS; Pradhan RS; Freeney T; Ji Q; Edeki T; Chiu W; Awni WM; Locke C; Schwartz LB; Granneman RG; O'Dea R
    J Clin Pharmacol; 2005 Aug; 45(8):910-8. PubMed ID: 16027401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
    Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
    J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of Paclitaxel-eluting stent restenosis with sirolimus-eluting stent implantation: angiographic and clinical outcomes].
    Byrne R; Iijima R; Mehilli J; Pache J; Schulz S; Schömig A; Kastrati A
    Rev Esp Cardiol; 2008 Nov; 61(11):1134-9. PubMed ID: 19000488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.